SCHEMBL73430

SCHEMBL73430

CCOC(=O)[C@H]1CC[C@H](OC(N2CCCC2)N2CCN(c3ccccn3)CC2)CC1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.46
ALDH1A1 P00352 11/20 0.46
KDM4E B2RXH2 7/20 0.46
MAPT P10636 6/20 0.46
TAAR1 Q96RJ0 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HSD17B10 Q99714 4/20 0.44
ATM Q13315 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL73431 1.00 HRH3 (0.46) HRH3ALDH1A1KDM4EMAPTTAAR1
SCHEMBL72774 0.83 MAPT (0.45) HRH3ALDH1A1KDM4EMAPTHTT
SCHEMBL72773 0.83 MAPT (0.45) HRH3ALDH1A1KDM4EMAPTHTT
SCHEMBL3352709 0.82 MAPT (0.57) ALDH1A1KDM4EMAPTHSD17B10ATM
SCHEMBL72207 0.79 ALDH1A1 (0.51) ALDH1A1KDM4EMAPTHTTKMT2A
SCHEMBL71446 0.79 ALDH1A1 (0.48) ALDH1A1KDM4EMAPTHTTKMT2A
SCHEMBL71447 0.79 ALDH1A1 (0.48) ALDH1A1KDM4EMAPTHTTKMT2A
Hydrochloric Acid SCHEMBL72206 0.78 ALDH1A1 (0.50) ALDH1A1KDM4EMAPTHTTKMT2A
Hydrochloric Acid SCHEMBL72208 0.78 ALDH1A1 (0.50) ALDH1A1KDM4EMAPTHTTKMT2A
SCHEMBL71462 0.75 GPR119 (0.46) ALDH1A1KDM4EMAPTHSD17B10ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1961750-A1 VLA-4 INHIBITORY DRUG Daiichi Sankyo Company, Limited (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 HRH3 314/4885ALDH1A1 216/4885KDM4E 983/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 HRH3 372/4885ALDH1A1 207/4885KDM4E 996/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 HRH3 247/4885ALDH1A1 525/4885KDM4E 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.